The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab: JCOG1308C.
 
Motoo Nagane
Honoraria - Eisai; Kyowa Kirin International; Nippon Kayaku; Ohara Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan; Nippon Shinyaku; Ohara Pharmaceutical; Ono Pharmaceutical; SERVIER
Speakers' Bureau - Nihon Medi-Physics; Novocure; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma; Daiichi Sankyo/UCB Japan (Inst); HOYA Techonosurgical (Inst); Johnson & Johnson/Janssen (Inst); Kyowa Kirin International; Nippon Kayaku; Ono Pharmaceutical; Saney Seiko (Inst); TERUMO
Travel, Accommodations, Expenses - Daiichi Sankyo/UCB Japan; Denka Co., Ltd; Eisai; Kyowa Kirin International; Nippon Kayaku; Novocure; Ohara Pharmaceutical; Ono Pharmaceutical; SERVIER
 
Keiichi Kobayashi
Travel, Accommodations, Expenses - Eisai
 
Riku Kajikawa
No Relationships to Disclose
 
Yoshiki Arakawa
Speakers' Bureau - Brainlab; Carl Zeiss Meditec; Chugai Pharma; Daiichi Sankyo; Eisai; Merck; Nihon Medi-Physics; Nippon Kayaku; Novocure; Ono Pharmaceutical; Stryker; UCB
Research Funding - Astellas Pharma; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Japan Blood Products Organization; Nihon Medi-Physics; Ono Pharmaceutical; Otsuka; Philips, Inc.; SERVIER; Stryker; Sumitomo Dainippon Pharma; Taiho Pharmaceutical
 
Noriyuki Kijima
No Relationships to Disclose
 
Shigeru Yamaguchi
Consulting or Advisory Role - Baxter Japan; Medtronic; UCB
Speakers' Bureau - Daiichi Sankyo; Eisai; Integra LifeSciences; Novocure; Ono Pharmaceutical
 
Yoshiko Okita
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Elekta; InSightec; Novocure; Nxera; Ono Pharmaceutical
 
Yoshiteru Shimoda
No Relationships to Disclose
 
Hirokazu Takami
Speakers' Bureau - Eisai
Research Funding - Astellas Co., Ltd.
 
Yukihiko Sonoda
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; CSL berhing; Daiichi Sankyo; Integra LifeSciences; Johnson & Johnson; Medtronic; Novocure; Nxera; Ono Pharmaceutical; Otsuka; Pfizer
Research Funding - Chugai Pharma; Otsuka; PDR pharma
 
Kazuhiko Mishima
Honoraria - Eisai; Novocure; Ohara Pharmaceutical; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Gunze (Inst); Kyowa Kirin (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); S and Brain (Inst); Stryker (Inst); Taiho Pharmaceutical (Inst)
 
Ichiyo Shibahara
Speakers' Bureau - Eisai; Ethicon; Novocure; Stryker; UCB
 
Takaaki Beppu
No Relationships to Disclose
 
Ryo Nishikawa
Consulting or Advisory Role - Novocure
 
Fumiyuki Yamasaki
No Relationships to Disclose
 
Koichi Ichimura
Honoraria - Bayer Yakuhin; Chugai Pharmaceuticals Co.,Ltd.; Eisai; Konica Minolta; Nippon Kayaku
Research Funding - Daiichi Sankyo; Riken Genesis Co.,LTD.,
Travel, Accommodations, Expenses - Chugai Pharmaceuticals Co.,Ltd.; Konica Minolta
 
Takashi Komori
No Relationships to Disclose
 
Keita Sasaki
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; m3.com
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); ONO PHARMACEUTICAL (Inst)
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Medi-Physics; Novocure; Ono Pharmaceutical; SERVIER; Sumitomo Dainippon Pharma Oncology
Consulting or Advisory Role - SERVIER; Sumitomo Pharma Oncology; SymBio Pharmaceuticals
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Incyte Japan (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); novocure (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PPD Global (Inst); Sumitomo Pharma Oncology (Inst); Taiho Pharmaceutical (Inst)